Stocks Health care QURE

NASDAQ · Health care

uniQure N.V. (QURE)

uniQure N.V. brought in $18.1M of revenue over the twelve months to March 31, 2026, down 10.4% from a year earlier. It posted a net loss of $208.9M. In fiscal 2025 capital spending exceeded operating cash flow by $178.4M. At March 31, 2026 it held $140M in cash against $49.9M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 29, 2026.

What uniQure N.V. does

uniQure N.V. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker QURE.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Where QURE ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What uniQure N.V. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 2, 2026
   Investor disclosure 8-K
2. August 14, 2026
   Passive stake changed SCHEDULE 13G/A
3. August 14, 2026
   Passive stake (5% or more) SCHEDULE 13G
4. July 29, 2026
   Employee stock plan registration S-8
5. July 29, 2026
   Quarterly report 10-Q · period to June 30, 2026
6. July 29, 2026
   Quarterly results 8-K
7. July 20, 2026
   Passive stake changed SCHEDULE 13G/A
8. July 16, 2026
   Passive stake (5% or more) SCHEDULE 13G
9. June 24, 2026
   Material agreement 8-K
10. June 24, 2026
    Securities offering prospectus 424B5

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 7, 2026. Insider transactions on SEC

Insider trades

What the people running uniQure N.V. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about QURE

What does uniQure N.V. do?

uniQure N.V. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker QURE.

Is uniQure N.V. profitable?

No. Over the twelve months to March 31, 2026 it reported a net loss of $208.9M on revenue of $18.1M.

How much revenue does uniQure N.V. make?

Over the twelve months to March 31, 2026 uniQure N.V. reported revenue of $18.1M. That is 10.4% less than a year earlier.

When did uniQure N.V. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on July 29, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 2, 2026.

Similar companies

Compare QURE with

Compare QURE with any company

Follow QURE

Get an email when uniQure N.V. files with the SEC: results, executive changes, material agreements and annual reports.

Follow QURE: get an email when it files

Where the numbers come from

Financial figures are the values uniQure N.V. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.